晚期胃癌患者化疗中胸腺肽α1治疗疗效的临床研究

目的：探讨应用流式细胞仪（FCM）检测胃癌患者外周血免疫指标,以评价胸腺肽α1联合化疗对胃癌患者免疫功能的影响。方法：70例胃癌患者随机分为用药组和对照组。用药组35例采用胸腺肽α1＋化疗,对照组35例单用化疗,两组化疗方案相同。胸腺肽α1每次1.6mg,每周2次,连续4周（共8针）。28天为一疗程,共用2个疗程。采用FCM检测两组患者化疗前后外周血CD4、CD8、CD3＋CD4＋、CD3＋CD8＋免疫指标。结果：用药组CD4、CD8、CD3＋CD4＋、CD4/CD8均高于化疗前和对照组化疗后水平,均具有统计学意义（P〈0.05）。结论：胸腺肽α1配合化疗能提高患者的免疫功能,用FCM检测外周血免疫指标为临床观察肿瘤患者的免疫状态提供有效的依据。

The Clinical Study of Thymosinα1 Therapeutic Effect of Chemotherapy in Advanced Gastric Cancer

Objective： Detecting peripheral blood immune parameters in patients with gastric cancer by Flow cytometry（FCM）,to evaluate the immune function in gastric cancer patients by the thymosinα1 combination chemotherapy.Methods： 70 patients with gastric cancer were randomly divided into treatment and control groups.Treatment group of 35 cases deploy thymosin α1 combination chemotherapy,35 patients in control group receive chemotherapy alone,two groups of chemotherapy schedule are identical.Thymosin α1 1.6mg every time,2 times per week,continuing 4 weeks（total 8 pin）.28 days for a course,keeping on 2 courses.By FCM,Two groups were detected CD4,CD8,CD3 ＋ CD4 ＋,CD3 ＋ CD8 ＋ in patients with peripheral blood before and after chemotherapy.Results： The level of CD4,CD8,CD3 ＋ CD4 ＋,CD4/CD8 in the treatment group were higher than those before chemotherapy and the control group after chemotherapy,There were statistically significant（P 0.05）.Conclusion： Thymosin α1 with chemotherapy can improve im-mune function in patients,to detect peripheral blood immune parameters by FCM provide an effective basis for clinical observation of the immune status of cancer patients.